ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 06 Jun 2022
Last Updated on 06 Jun 2022
A- A+
Guidance Recommendation
The Ministry of Health’s MTAC has not recommended subsidy for coronary intravascular lithotripsy (IVL) for treating severely calcified, stenotic de novo coronary artery.

Subsidy status

Coronary IVL is not recommended for subsidy in patients with the abovementioned indications. 


Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery